An evaluation of the Sherwood S-12 system for use with the SMA 12/60 by Kankoski, Thomas
Rochester Institute of Technology
RIT Scholar Works
Theses Thesis/Dissertation Collections
12-1-1977
An evaluation of the Sherwood S-12 system for use
with the SMA 12/60
Thomas Kankoski
Follow this and additional works at: http://scholarworks.rit.edu/theses
This Thesis is brought to you for free and open access by the Thesis/Dissertation Collections at RIT Scholar Works. It has been accepted for inclusion
in Theses by an authorized administrator of RIT Scholar Works. For more information, please contact ritscholarworks@rit.edu.
Recommended Citation
Kankoski, Thomas, "An evaluation of the Sherwood S-12 system for use with the SMA 12/60" (1977). Thesis. Rochester Institute of
Technology. Accessed from
AN EVALUATION OF THE SHERWOOD S-12 SYSTEM 
FOR USE WITH THE SMA 12/60 
THOMAS KANKOSKI 
DECEMBER, 1977 
THESIS 
SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE 
APPROVED: 
Rochester Institute of Technology 
Rochester, New York 14623 
Department of Chemistry 
A. Bacharach 
Project Advisor 
R. E. Gilman 
Department Head 
Name(s) Illegible 
Library 
t/'
VITAE
The author was born on December 23, 1948 in Syracuse, New York
where he received his elementary and high school education.
He enrolled at the State University of New York College at
Brockport in September, 1966 and was awarded a Bachelors of Science
Degree in Chemistry in May, 1970.
From November, 1970 to June, 1973 the author was employed as a
clinical technologist in the Clinical Chemistry Laboratory at the
University of Rochester Medical Center.
In August, 1973 the author was enrolled at the University of
Arizona, College of Pharmacy as a doctoral candidate in Pharmacology.
He withdrew from the University of Arizona in June, 1974 before the
granting of a degree.
The author resumed employment as a supervisor in the Clinical
Chemistry Laboratory at the University of Rochester Medical Center,
where he is currently employed.
The author was enrolled in September, 1975 as a part-time
candidate for the Master of Science Degree in Clinical Chemistry at
the Rochester Institute of Technology under Dr. William Bigler and
Dr. Alfred Bacharach.
The author is a member of the American Association for Clinical
Chemistry.
^^
ACKNOWLEDGEMENTS
I am grateful to the Clinical Chemistry Laboratory at the
University of Rochester Medical Center for giving me the opportunity
to complete my graduate studies.
A sincere thanks is offered to Mr. James Salvatore for his
many helpful comments during the preparation of this thesis. The
dedication that Mr. Salvatore has consistently displayed toward
clinical chemistry has been an admirable example and a source of
personal inspiration.
My sincere appreciation is extended to Dr. Alfred Bacharach for
his capable direction and encouragement in completing this thesis.
Dr. Bacharach 's devotion to the pursuit of knowledge has been
a great source of encouragement in the continuation of my education.
I would like to express my gratitude to Ms. Paula Brink for her
patience and fine effort in producing this manuscript.
^.^^
TABLE OF CONTENTS
Page
Vitae ii
Acknowledgements Hi
Table of Contents iv
List of Tables vi
List of Figures vii
Introduction 1
Experimental 4
Technicon SMA 12/60 4
Sherwood S- 12 System 5
Reagents 5
Reference Standard 6
Control Samples 6
Human Serum 6
Chemical Methods 6
Operational Protocol
Within Run Precision 9
Day to Day Precision 9
Patient Comparison 9
Linearity 9
Carryover 10
Drift 10
Software Modification 11
Statistical Methods 11
iv
Page
Acceptance Criteria 12
Results and Discussion 14
Carryover 14
Drift 18
Linearity 21
Total Protein 23
Albumin .*. . 23
Calcium 23
Phosphorus 27
Cholesterol 29
Urea 29
Uric Acid 32
Creatinine 32
Bilirubin 32
Alkaline Phosphatase 36
Lactate Dehydrogenase 36
Aspartate Aminotransferase 36
Operational Parameters 41
Conclusion 45
Footnotes 47
Bibliography 48
Appendices 50
Abbreviations 51
Linear Regression Graphs 52
Clinically Acceptable Coefficients of Variation. 76
v
LIST OF TABLES
Table Page
1 Carryover S-12 15
2 Carryover SMA 12/60 16
3 Carryover Comparison 17
4 Drift Comparison 19
5 Linearity Limits 22
6 Comparison Data, Total Protein 24
Comparison Data, Albumin 25
8 Comparison Data, Calcium 26
9 Comparison Data, Phosphorus 28
10 Comparison Data, Cholesterol 30
11 Comparison Data, Urea 31
12 Comparison Data, Uric Acid 33
13 Comparison Data, Creatinine 34
14 Comparison Data, Bilirubin 35
15 Comparison Data, Alkaline Phosphatase 37
16 Comparison Data, Lactate Dehydrogenase 38
17 Comparison Data, Aspartate Aminotransferase 39
18 Rejected Values, SMA 12/60 vs S-12 44
19 Summary of S- 12 Study 46
vx
LIST OF FIGURES
Figure Page
1 Theoretical Deformation of a 12/60
Chemistry Curve 42
2 Theoretical Deformation of an S-12
Chemistry Curve 43
vii
INTRODUCTION
The Technicon SMA 12/60 is a continuous flow, multichannel led,
biochemical analyzer. It is designed to sequentially analyze twelve
constituents of a serum specimen with a throughput of sixty samples
per hour. When initially introduced into the clinical laboratory the
sampling rate of sixty samples per hour proved adequate. Recently,
however, many laboratories have been confronted with increasing
workloads and decreasing budgets. Consequently, a need has
developed to extract maximum productivity from existing equipment.
This need has prompted research into factors which limit sampling
rates of continuous flow devices .
Skeggs first observed that the rate of analysis by continuous
flow was limited by the degree of sample interaction. This led to the
introduction of the air bubble as a means of separating samples and
reagents in a moving stream. More recently Thiers et al (1,2) have
defined some of the characteristics of segmented and non-segmented
flow. It has been shown that there are two components to sample
interaction: interaction in the unbubbled stream and interaction
in the bubbled stream. Output data from continuous flow devices
may be mathematically manipulated to separate these two sources of
interaction. When this is done, the interaction in the unbubbled
stream can be defined as a straight line with a slope that is constant
for a given system. Consequently, the degree of sample interaction
can be predicted and an accurate correction can be made. Several
authors have described methods for accomplishing this correction
(3,4,5,6).
Interaction in the bubbled stream is considerably less than in
the unbubbled stream. Moreover, the nature of this interaction is
more complex and difficult to define in mathematical terms. A
reliable means of correcting for this type of interaction has yet
to be developed.
Computers have been used successfully in correcting for sample
interaction on both single channel (6) and multichannel (5)
instruments . Sampling rates of greater than 100 per hour have been
attained. This success has led to the hope that the larger
multichannelled instruments such as the SMA 12/60 could also attain
rates in excess of 100 specimens per hour. Several manufacturers
have undertaken projects to design and market mini- computer or
microprocessor devices that will allow for faster sampling rates
on the SMA 12/60. Evaluation of one such microprocessor programmer
device will form the basis of this thesis. Specifically the study
of the S-12 System was divided into two categories. First an
assessment of the relevant technical parameters and second an
assessment of pertinent operational characteristics.
Technical parameters evaluated included within run and day to
day precision, accuracy (as determined by comparison with SMA 12/60) ,
drift and linearity. Sample interaction at various levels is also
determined.
Operational parameters evaluated included number and reliability
of error messages and degree of operator instrument interaction.
EXPERIMENTAL
Technicon SMA 12/60
The Technicon SMA 12/60 is a 12 channel continuous flow analyzer
manufactured by Technicon Instrument Corporation, Tarrytown, New
York. The instrument was purchased by the University of Rochester -
Clinical Chemistry Laboratory in 1969 and refurbished in 1972.
Daily maintenance is performed by the technical staff in the Clinical
Chemistry Laboratory which uses the instrument for routine testing.
The problem of sample interaction is dealt with on the SMA 12/60
by allowing each sample to achieve a steady state plateau as it
passes through the colorimeter. This allows for almost complete
washout between samples resulting in minimal interaction. For
optimal washout the sampling rate is limited to 60 samples per
hour.
Timing for each steady state plateau is controlled by an
electronic programmer. The programmer reads the signal from each
channel on an intermittent synchronized basis. Phase relationships
between channels are determined by the flow rate and the volume
through which the sample must travel before entering the colorimeter.
Volumes are adjusted by use of phasing coils of appropriate size.
Calibration is accomplished by manually setting a reference
standard to predetermined values.
Results are traced on a strip chart recorder. For routine
use the SMA 12/60 is interfaced with an Infotronics A/D convertor
which takes an analog signal from the recorder slidewire and converts
it to a digital signal which is ultimately printed on a Decwriter.
Sherwood S-12 System
The S-12 System consists of a microprocessor-programmer unit and
a teletype command module. The microprocessor-programmer by-passes
the SMA 12/60 electronics by taking a signal directly from the
photodetectors . Each channel is monitored continuously, obviating
the need for manual phasing. Data thus obtained is submitted to
various curve analysis algorithms to correct for sample interaction
and determine actual concentration.
The S-12 is self calibrating. When reference standard (calibrating
material) is placed in predetermined tray positions, the S-12 will
automatically adjust to the concentration set points which have
been previously inputted into the system. Recalibration is effected
by the following equation:
recalibration value = previous value + present value * 2.
This method of recalibration partially compensates for instrument
drift.
The S-12 System increases the sampling rate of the SMA 12/60
to 120 per hour. Results (corrected for sample interaction) are
printed in digital form by the teletype command module.
Reagents
Bromocresol green reagent for use in the albumin determination
was purchased from Technicon Instrument Corporation. Cholesterol
oxidase reagent for use in the cholesterol determination was
purchased from Boehringer Mannheim Corporation. All other SMA
12/60 reagents were purchased from Fisher Scientific.
Reference Standard
Lyophilized human serum was purchased from Fisher Scientific.
Set points were based on values obtained within the laboratory as
well as from the manufacturer.
Control Samples
Control samples consisted of lyophilized human serum purchased
from Hyland Division Travenol Laboratories, Inc. Two levels
(abnormal IPA-1 and normal IPN-1) were used in this study.
Human Serum
Serum used in comparison studies was obtained from routine
patient specimens submitted to the Clinical Chemistry Laboratory
for analysis.
Chemical Methods
All chemical methods on the SMA 12/60, with the exception of
the cholesterol method, were performed according to the specifications
of Technicon Instruments Corporation, Technical Publication No.
UA4-0160B00, April, 1974. The cholesterol oxidase method was
performed according to the details supplied by Boehringer Mannheim
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Corporation (package insert) . The modification for use with the
albumin pre-dilution manifold was employed.
The test sequence on the 12/60 used was as follows : total
protein, albumin, calcium, phosphorus, cholesterol, urea, uric
acid, creatinine, bilirubin, alkaline phosphatase, LDH, AST.
Operational Protocol
SMA 12/60
Routine analysis of patient sera was performed daily on the
SMA 12/60. Data used in this study was obtained in conjunction with
these routine daily runs. No special treatment was given to specimens
analyzed by the SMA 12/60. Acceptability of data was determined
according to standard laboratory protocol which involves checking
a lyophilized control against predetermined limits (+2SD) and
checking calibration standards for drift. If a control value was
outside +3SD or the drift exceeded 10% the data for that section
was rejected.
Trays were loaded according to the following scheme:
cups 1-3, 15,16,28,29,40 reference standard
cups 9,22,35 control sample
cups 4-8, 10-14, 17-21, 23-27, 30-34, 36,39 patient sera.
Cup 1 was a prime standard, cups 2,3,16 and 29 were calibration
standards. Standards in cups 15,28 and 40 were used as drift
standards and were not set by the operator.
SMA 12/60 with S-12
After completion of the routine work for the day the SMA 12/60
was shut down. The S-12 unit was attached by interchanging six
cables and the combined system was restarted immediately.
After installation of the S-12 System a pilot run consisting
of normal and abnormal controls was run to ascertain the integrity
of all channels .
Acceptability of data was determined in a manner similar to that
of the SMA 12/60 data. Accurate ranges for controls were not
available for the S-12 System hence a more liberal interpretation
of data was allowed.
Trays were loaded according to the following scheme:
cup 0-phase + prime standard (contains ink)
cup 1,11,21,31 calibration/drift standards
cup 2 water
cup 3 calibration check standard
cups 7,16,26,35 control samples
cups 4-10, 12-20, 22-30, 32-39 unknowns.
The standard in cup 0 was used to determine the characteristic
shape of the chemistry curves and the timing relationships between
specimens. The water following the calibration standard (cup 2)
was used to determine a carryover correction factor for each
channel. This factor was automatically applied to all subsequent
data.
Within Run Precision
Within run precision was determined by analyzing a full tray
of reference standard on each of two different days . Means and
coefficients of variation were calculated for each channel.
Day to Day Precision
Day to day precision was determined by analyzing two levels
of lyophilized control samples on different days. If a control
was run more than once, one value was selected at random. Means
and coefficients of variation were computed for each channel. Day
to day precision studies encompassed 14 days prior to software
modification and 8 days following modification.
Patient Comparison
Approximately 100-200 patient specimens were analyzed first
with the SMA 12/60 alone and then with the SMA 12/60 - S-12
combination. SMA 12/60 serum specimens were taken from their trays
after analysis, aliquoted into smaller cups, capped and reanalyzed
within 12 hours with the S-12 unit in place. Specimens were stored
at either room temperature or at 4 C.
Linearity
Linearity was determined by analyzing either pooled patient
sera or lyophilized human serum. Serial dilutions of serum were
made with 6% bovine albumin in 0.9% saline. Lyophilized serum was
reconstituted to two thirds original volume with matched diluent.
Dilutions of this concentrate were made with the same diluent.
Linearity studies were repeated on at least two different days.
Carryover
Carryover (sample interaction) was determined by analyzing
lyophilized human serum in the following sequence:
1) water
2) dilute serum (A)
3) concentrated serum (B)
4) dilute serum (identical with A) (A')
The degree that the concentrated serum carried over into the
dilute serum was calculated by the equation: % carryover=A -A x 100.
B
Various levels of A and B were employed. Average values for
eight determinations on three different days were computed.
Drift
Drift refers to the observed deviation of the calibration
standard from the predetermined value set by either the operator
or the microprocessor. Drift on the 12/60 was determined by
subtracting values obtained for the drift standard (cups 15,28 and 40)
from those values set in cups 3,16 and 29. Drift was then the
observed change every twelfth cup. With the S-12 unit attached
values for the calibration standard were printed out before they
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were reset by the microprocessor. These values were subtracted
from the values programmed into the microprocessor. Drift was then
the observed change every tenth cup.
Software Modification
During the course of evaluation two channels (calcium and AST)
gave results that were obviously unacceptable. In an attempt to
remedy this situation the manufacturer rewrote the peak sensing
algorithm. This new algorithm was programmed into the microprocessor.
The preceding experiments were then repeated in a somewhat abbreviated
form with the exception of the within run precision and carryover
experiments .
Statistical Methods
Two types of "t" tests were employed for statistical analysis of
comparison data. A two sample "t" test was used to test for a
significant difference between means of controls (7) and a one sample
"t"
test was used to determine if a significant bias existed between
patient specimens (7) .
A standard "F" test was used to determine if the difference
in precision between methods was significant (7) .
Least squares regression analysis was performed as described
by Draper and Smith (8) .
All probabilities were taken at p < 0.05 based on tables
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generated by International Mathematical and Statistical Library
programs (9). All statistical calculations were performed by a
DEC 10 computer.
Guidelines for interpretation of "t" tests, linear regressions,
correlation coefficients and biases may be found in the articles
by Westgard (10,11).
Acceptance Criteria
The acceptability of results was judged at both the statistically
significant level and the clinically significant level. As previously
noted all statistical limits were taken at p <0.05.
Clinical significance is determined by a number of factors
including: degree of variation within individuals, degree of variation
between individuals, levels of physiological significance and manner
in which a test result is used (e.g. treatment, diagnosis, etc.).
Because these factors are often ill defined, an element of subjectivity
is introduced when setting the level of clinical significance. Two
authors have attempted to define a level of clinical significance
relative to the day to day precision of some laboratory tests.
Barnett (12) determined clinically acceptable coefficients of
variation for a number of tests by discussions with laboratory and
clinical personnel. This approach accounts for the manner in which
tests are used. By determining similar values based upon actual
biological variations in normal subjects, Cotlove (13) accounted for
day to day variation within individuals. Thus by averaging
Barnett' s
and
Cotlove' s values, two of the factors influencing clinical significance
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can be accounted for. For the purpose of this study an average of
these values was chosen as the limit of clinical acceptability for
day to day precision. A summary of Barnett 's and Cotlove 's findings
may be found in the appendix.
No reports, similar to those of Cotlove and Barnett, pertaining
to the clinical acceptability of patient comparison data were found
in the literature. Accordingly, a relatively larger element of
subjectivity was introduced into the interpretation of these results.
The greatest importance was assigned to the slope, y-intercept
and bias when comparing patient specimens. Less importance was
assigned to the "t" test and correlation coefficient since these
terms give only a relative indication of the magnitude of error and
are easily influenced by a number of factors (11) . Consideration
was given to the normal range, within individual variation (Cotlove)
and clinical usefulness of the test when interpreting patient
comparison data. With the exception of bilirubin and calcium a
difference between methods of 5% or less is not regarded as significant
in this laboratory. The sensitivity and normal range (0.1 to 1.0
mg/dl) of the bilirubin method allows for the extension of the
acceptable limit to 10%. The clinical and physiological importance
of serum calcium necessitate a tighter limit of 3%.
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RESULTS AND DISCUSSION
Carryover
The results of the carryover experiments are shown in Tables 1-3.
Each value of A and B represents the mean of three concentrations
obtained on three different days. It should be noted that the calcu
lated percent carryover reflects the interaction of water with the
first low specimen (A) , as well as the interaction of the higher
specimen (B) with the second low specimen (A) . In practice each
sample is not preceded by water but by another sample, and therefore,
the determined values cannot be used as a quantitative measure of
carryover during routine analysis of samples.
Since the S-12 is designed to automatically correct for carryover,
one would expect the percent carryover of the S-12 to be less than the
12/60. This was the case for all channels except calcium and AST. Here
the S-12 yields a slightly higher carryover for the calcium channel
and a substantially higher carryover for the AST channel. The observed
carryover in the calcium channel, of itself, is not significant,
but may be expected to contribute to the total error of the channel.
On the other hand, the carryover present in the AST channel may have
a more pronounced affect on the total error. This error may be
magnified by the relatively large variability in activities of patient
sera (10-300 IU/1) . Based on the results of the carryover experiments
it would appear that the carryover correction algorithm is inadequate
for the calcium and AST channels.
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TEST
CARRYOVER S-12
CO. = A1 -A x 100
B
% CO.
Total Protein 8.3 3.1 0.23
Albumin 4.6 1.9 0.43
Calcium 14.3 4.7 1.92
Phosphorus 7.3 2.6 0.50
Cholesterol 223.0 86.0 1.26
Urea 76.0 27.0 1.47
Uric Acid 9.7 3.7 0.96
Creatinine 6.6 2.3 0.00
Bilirubin 2.7 0.8 1.38
Alk Phos 120.0 50.0 0.31
LDH 353.0 144.0 0.66
AST 104.0 29.0 7.27
TABLE 1
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TEST
CARRYOVER SMA 12/60
% CO. = A'-A x 100
B
% CO.
Total Protein 8.3 3.5 7.55
Albumin 4.8 2.3 0.85
Calcium 14.9 6.0 1.64
Phosphorus 7.4 3.2 1.00
Urea 82.0 34.0 1.83
Uric Acid 10.1 4.5 3.08
Creatinine 6.9 2.8 1.27
Bilirubin 3.0 1.4 7-75
Alk Phos 117.0 58.0 2.08
LDH 403.0 170.0 2.38
AST 103.0 37.0 1.91
TABLE 2
16
CARRYOVER COMPARISON
TEST % CO.
SMA 12/60
Total Protein 7.55
Albumin 0.85
Calcium 1.64
Phosphorus 1.00
Urea 1.83
Uric Acid 3.08
Creatinine 1.27
Bilirubin 7.75
Alk Phos 2.08
LDH 2.38
AST 1.91
% CO.
S-12
0.23
0.43
1.92
0.50
1.47
0.96
0.0
1.38
0.31
0.66
7.77
TABLE 3
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Drift
Strictly defined drift is the observed change in concentration
over a period of time. For the purpose of this discussion, drift
is expressed as the change in observed concentration of the
calibrator between the first and twelfth (12/60) or tenth (S-12)
consecutive measurement. This definition allows for practical
rather than theoretical considerations. The microprocessor cannot
distinguish between a continuous, incremental or random change in
calibrator concentration and will recalibrate solely on the basis
of the present and previous values of the calibrator. Since
recalibration is independent of the origin of the deviation from
the set point, a minimal change, whatever the cause, is necessary
to ensure accurate calibration.
The average drift, over fourteen days, was determined for both the
12/60 and the S-12 (Table 4). The drift for the S-12 was greater
than that for the 12/60 in five instances, however, the greater drift
observed for the total protein, uric acid and LDH channels would not
be expected to significantly affect their overall performance.
The drift found in the calcium channel was not reflected in the
within run precision studies. Not only was there an absence of a
unidirectional variation, but the within run variation was one third
that of the observed drift. This implies that the observed deviation
of the standard from its set point occurred in a random manner. This
observation may partially be explained in terms of carryover. Since
the same specimen was analyzed sequentially during within run precision
18
DRIFT COMPARISON
TEST AVERAGE DRIFT
SMA 12/60
AVERAGE DRIFT
S-12 '" TEST
Total Protein
Albumin
Calcium
Phosphorus
Urea
Uric Acid
Creatinine
Bilirubin
Alk Phos
LDH
AST
0.060 g/dl
0.068 g/dl
0.082 mg/dl
0.117 mg/dl
1.18 mg/dl
0.074 mg/dl
0.054 mg/dl
0.115 mg/dl
1.82 IU/1
4.94 IU/1
2.27 IU/1
0.139 g/dl
0.094 g/dl
0.348 mg/dl
0.126 mg/dl
0.943 mg/dl
0.160 mg/dl
0.048 mg/dl
0.031 mg/dl
0.977 IU/1
8.00 IU/1
8.10 IU/1
TABLE 4
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studies, the effect of sample interaction was negligible, i.e. each
sample interacted with an identical sample. However, in the drift
experiments, samples of different concentrations were placed
between standards and thus carryover may have contributed to the
observed variation.
The drift found in the AST channel was reflected in the within
run precision studies. While no unidirectional change was observed,
the within run precision approximated the variation found in the
reference standard.
It is also of interest to note that the average drift* in the
AST channel exceeds the preset limits for the triggering of a calibra
tion error message. An error message is obtained if:
So - So + Sp .. So + Sp > Q 04
where So is the present observed standard concentration and Sp
is the previously stored value for the standard. This was confirmed
in practice by the high incidence of calibration error messages
obtained on the AST channel.
The difficulties encountered with the AST channel are best
explained in terms of the peak sensing algorithm. The AST method is
dependent upon a decrease rather than an increase in absorbance,
together with a relatively high gain. Thus the curve sensing algorithm
designed for the typical colorimetric channels may not be adequate
for the AST channel. When the peak sensing algorithm was rewritten,
the observed average drift for the AST channel was reduced from 10.8%
to 3.7%.
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Linearity
The results of the linearity studies are shown in Table 5.
Concurrent linearity studies were not performed on the 12/60 due
to sample and time limitations. The values shown for the 12/60 are
the limits accepted by the Clinical Chemistry Laboratory for
routine use. Values shown for the S-12 were determined on at least
two different days. These values do not necessarily represent the
*
uppermost limit of linearity for the S-12 but reflect the highest
values observed with available specimens. The values shown for
albumin, LDH and AST are exceptions and represent the concentration
where the response is no longer linear. An assessment of albumin
linearity on the 12/60 gave results comparable to those obtained
with the S-12. This apparent loss of linearity was attributed to
an insufficient quantity of wetting agent in the albumin color
reagent .
The linearity limits on the 12/60 are partially restricted by
the electronics. The strip chart recorder on the 12/60 will accept
a maximum signal of 50 millivolts, thus even though the response
of a channel may be linear beyond the 50 millivolt range, the
instrument cannot make the appropriate measurement. The S-12
is not dependent upon the strip chart recorder for operation;
which explains why the linearity limits may be extended for some
channels .
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LINEARITY LIMITS
TEST SMA 12/60
(ACCEPTED)
S-12
(OBSERVED)
MATERIAL
ANALYZED
Total Protein
Albumin
Calcium
Phosphorus
Cholesterol
Urea
Uric Acid
Creatinine
Bilirubin
Alk Phos
LDH
AST
10.0 g/dl
5.0 g/dl
15.0 mg/dl
10.0 mg/dl
500.0 mg/dl
100.0 mg/dl
12.0 mg/dl
15.0 mg/dl
10.0 mg/dl
350.0 IU/1
600.0 IU/1
300.0 IU/1
10.0 g/dl
3.5 g/dl
18.0 mg/dl
12.0 mg/dl
360.0 mg/dl
119.0 mg/dl
12.2 mg/dl
10.2 mg/dl
18.7 mg/dl
800.0 IU/1
650.0 IU/1
600.0 IU/1
bovine albumin
reference serum
reference serum
patient sera
patient sera
patient sera
patient sera
patient sera
patient sera
patient sera
patient sera
patient sera
TABLE 5
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Total Protein
The overall performance of the total protein channel was
judged as acceptable (Table 6). While the precision was found to
be statistically poorer for the S-12 in two instances, the obtained
coefficients of variation were still well within the clinically
acceptable limit, 3.7%.
Patient comparison studies indicated a relatively small
proportional (5%) and constant (-0.15 g/dl) error.
Albumin
The results obtained with the S-12 System for albumin were
comparable to those obtained with the SMA 12/60 as shown in
Table 7. In only one instance (precision for IPA control after
software modification) was a statistically significant difference
obtained. Virtually no bias was observed among patient specimens.
The low correlation coefficients obtained are probably due to the
narrow range of serum albumin concentrations investigated, typically
2.0 to 5.0 g/dl.
Calcium
The performance of the calcium channel was found to be
unacceptable. The data obtained is shown in Table 8. While no
statistically significant difference was seen in day to day
precision between the S-12 and the 12/60, the S-12 yielded somewhat
23
COMPARISON DATA
TOTAL PROTEIN
Within Run Precision
Day Mean CV. n
1 6.30 2.54 32
2 6.63 1.21 32
Day to Day Precision
Control 12/60
x (n)
S-12
x (n)
12/60
CV.
S-12
CV.
""
test
trpn
test
Abnormal 6.29 (30) 6.30 (14) 1.40 2.98 - +
Normal 5.06 (30) 5.03 (14) 1.80 1.95 - -
Abnormal* 6.29 (30) 6.44 (8) 1.91 2.33 + -
Normal* 5.09 (30) 5.21 (8) 1.65 2.82 - +
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int >t
I 113 1.051 -0.191 0.9863
II* 241 1.049 -0.110 0.9773
'"
test
*Data obtained after software modification.
TABLE 6
bias
-0.146
-0.216
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COMPARISON DATA
ALBUMIN
Within Run Precision
Day Mean CV. n
1 3.59 1.53 32
2 3.71 1.62 32
Day to Day Precision
Control 12/60
x (n)
S-12
x (n)
12/60
CV.
S-12
CV.
""
test
npn
test
Abnormal 3.76 (30) 3.76 (14) 3.43 2.71 - -
Normal 3.10 (30) 3.05 (14) 3.42 2.80 - -
Abnormal* 3.64 (30) 3.59 (8) 2.77 4.37 - +
Normal* 3.00 (30) 2.94 (8) 4.36 4.39 _ _
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int n.
I 163 1.030 -0.098 0.9766
II* 240 0.951 0.153 0.9355
'"
test
*Data obtained after software modification.
TABLE 7
bias
-0.012
0.026
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COMPARISON DATA
CALCIUM
Within Run Precision
Day Mean CV. n
1 10.84 1.11 32
2 10.87 0.91 32
Day to Day Precision
Control 12/60 S-12 12/60 S-12 "" "F"
x (n) x (n) CV. CV. test test
Abnormal 12.04 (30) 12.30 (14) 1.93 2.44 +
Normal 9.07 (30) 9.23 (14) 1.81 2.23
Abnormal* 11.97 (30) 12.24 (8) 1.16 2.70 - +
Normal* 9.05 (30) 9.24 (8) 1.86 2.40 +
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
'" test bias
+ -0.110
+ -0.146
n slope y-int ft
I 119 0.947 0.582 0.9008
II* 241 0.954 0.560 0.9669
*Data obtained after software modification.
TABLE 8
26
higher coefficients of variation. For this particular analysis a
slight deterioration in precision may be crucial. Barnett (12)
has suggested a coefficient of variation of 2.3% as acceptable
for the measurement of serum calcium, while Cotlove (13) has
suggested a value of 1.6%. All the coefficients of variation obtained
with the S-12 exceed the average value of 2.0%. On this basis,
the performance of the S-12 would be unacceptable for the measurement
of calcium.
The lyophilized control material also indicated a bias of
about 0.2 mg/dl between the 12/60 and S-12. The bias was somewhat
less for patient sera (0.1 mg/dl) but a high level of constant
error was observed (y int = 0.6). Correlation with the 12/60 was
poor during the first trial (0.9008) and improved only slightly after
the software was modified (0.9669). Overall the redesigned peak
sensing algorithm had little effect in improving the performance of
the channel.
Phosphorus
Table 9 summarizes the data obtained for the phosphorus
channel. This channel was found to be acceptable. Statistically
higher coefficients of variation were obtained with the S-12 in
three of four instances, however, they were all well within the
clinically acceptable limit of 6.1%. Similarly the three positive
"" tests were of little clinical import.
27
COMPARISON DATA
PHOSPHORUS
Within Run Precision
Day Mean CV. n
1 5.37 1.30 32
2 5.57 2.33 *32
Day to Day Precision
Control 12/60
x (n)
S-12
x (n)
12/60
CV.
S-12
CV.
""
test
npn
test
Abnormal 7.05 (30) 7.21 (14) 1.83 2.76 + +
Normal 3.17 (30) 3.13 (14) 1.83 3.13 - +
Abnormal* 6.89 (30) 7.07 (8) 1.46 2.38 + +
Normal* 3.16 (30) 3.09 (8) 2.25 2.69 + _
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int A.
I 164 0.990 0.039 0.9826
II* 236 1.018 -0.066 0.9924
'" test
*Data obtained after software modification.
TABLE 9
bias
-0.004
0.005
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Patient comparison studies indicated virtually no bias
between methods. A small, (1-2%) but insignificant proportional
error was found.
Cholesterol
During the course of the S-12 evaluation the Clinical Chemistry
Laboratory changed the SMA 12/60 cholesterol methodology from the
Liebermann-Burchard method to the cholesterol oxidase method.
Consequently no comparison data is available prior to the software
modification. All cholesterol data shown for the S-12 System was
obtained with the cholesterol oxidase method.
The performance of the cholesterol channel was judged to be
acceptable, however, significantly poorer precision was obtained at
both levels of control (Table 10) . Cotlove (13) suggests an
allowable error of 8.2% for cholesterol, which would make the
observed average value of 7.1% acceptable. Nonetheless, this
value is almost a factor of two greater than that obtained with
the 12/60. The data collected after the software change was limited
(n=8) , and undoubtedly influenced the reliability of the determined
coefficient of variation. Patient specimens compared favorably
as evidenced by the slope, y-int and bias.
Urea
The performance of the urea channel was acceptable. Table 11
summarizes the data for this channel. No bias in patient specimens
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COMPARISON DATA
CHOLESTEROL
Within Run Precision
Day Mean CV. n
2 164.4 2.04 32
Day to Day Precision
Control 12/60 S-12 12/60 S-12 "" "F"
x (n) x (n) CV. CV. test test
Abnormal 163.4 (14) 4.54
Normal 123.6 (14) 6.57
Abnormal* 169.9 (30) 160.9 (8) 3.50 9.05 - +
Normal* 132.4 (30) 122.1 (8) 3.99 8.31 + +
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int n. "" test bias
I
II* 103 0.995 -1.362 0.9842 + 2.24
*Data obtained after software modification.
TABLE 10
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COMPARISON DATA
UREA
Within Run Precision
Day Mean CV. n
1 57.0 1.16 32
2 57.5 0.99 32
Day to Day Precision
Control 12/60
x (n)
S-12
x (n)
12/60
CV.
S-12
CV-
""
test
npn
test
Abnormal 44.4 (30) 45.9 (14) 2.08 2.40 + -
Normal 21.6 (30) 21.7 (14) 2.87 2.26 - -
Abnormal* 44.4 (30) 46.0 (8) 1.63 1.94 + -
Normal* 21.4 (30) 22.1 (8) 3.13 3.16 + _
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int ft
I 159 1.015 -0.365 0.9986
II* 244 1.049 -0.625 0.9963
'" test
*Data obtained after software modification.
TABLE 11
bias
0.063
-0.209
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was observed and only slight biases in control material could be
demonstrated.
Uric Acid
The performance of the uric acid channel was acceptable
(Table 12) . While significantly poorer precision was noted for the
high control the value observed was well within the clinically
acceptable limit of 10.3%. No significant bias was detected in
either the lyophilized controls or patient sera. Patient sera
correlated well (0.995) and showed little proportional (3%) and
constant (0.2 mg/dl) error.
Creatinine
The S-12 compared favorably to the 12/60 for creatinine
(Table 13) . Statistically measurable biases were found but were of
no clinical import. For example, since creatinine results are
reported to the first decimal, the observed bias of 0.04 mg/dl
for patient sera is insignificant.
Bilirubin
The overall performance of the bilirubin channel was acceptable
(Table 14) . Note that the slope of the regression line for patient
sera increased from 0.914 to 1.063 after the software was modified.
This increase was also reflected in the biases of both controls.
These observations were probably not related to the software
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COMPARISON DATA
URIC ACID
Within Run Precision
Day Mean CV. n
1 7.50 0.80 32
2 7.60 1.31 32
Day to Day Precision
Control 12/60
x (n)
Abnormal 9.40 (30)
Normal 4.56 (30)
Abnormal* 9.30 (30)
Normal* 4.60 (30)
S-12
x (n)
9.39 (14)
4.55 (14)
9.40 (8)
4.53 (8)
12/60
CV.
0.94
1.36
1.26
1.93
S-12
CV.
2.15
1.14
1.99
2.34
""
test
npii
test
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int n.
I 161 1.020 0.176 0.9979
II* 247 1.039 -0.238 0.9908
'" test
*Data obtained after software modification.
TABLE 12
bias
0.059
0.006
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COMPARISON DATA
CREATININE
Within Run Precision
Day Mean CV. n
1 4.87 1.03 32
2 4.93 1.01 32
Day to Day Precision
Control 12/60
x (n)
Abnormal 5.17 (30)
Normal 1.60 (30)
Abnormal* 5.10 (30)
Normal* 1.63 (30)
S-12
x (n)
5.12 (14)
1.59 (14)
5.19 (8)
1.58 (8)
12/60
CV.
1.22
2.56
1.55
4.17
S-12
CV.
0.69
1.82
1.68
3.16
""
test
"P"
test
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int * "" test bias
I 156 1.027 -0.080 0.9991 + 0.040
II* 249 1.018 -0.053 0.9955 + 0.033
*Data obtained after software modification.
TABLE 13
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COMPARISON DATA
BILIRUBIN
Within Run Precision
Day Mean CV. n
1 2.14 2.34 32
2 2.16 2.31 32
Day to Day Precision
Control 12/60
x (n)
Abnormal 4.70 (30)
Normal 1.48 (30)
Abnormal* 4.26 (30)
Normal* 1.37 (30)
S-12
x (n)
4.74 (14)
1.50 (14)
4.49 (8)
1.50 (8)
12/60
CV.
3.13
4.12
3.61
3.65
S-12
CV.
3.37
0.03
3.83
7.33
""
test
"P"
test
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
n slope y-int H
I 148 0.914 -0.039 0.9820
II* 235 1.063 -0.110 0.9947
'" test
*Data obtained after software modification.
TABLE 14
bias
0.123
0.058
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modification but most likely resulted from difficulties with the
chemistry and hydraulics of the bilirubin channel. The fact
that the shift in control means was less for the S-12 than for the
12/60 suggests that the S-12 partially compensated for the problem.
Alkaline Phosphatase
The performance of the alkaline phosphatase channel was acceptable
(Table 15) . Substantially larger coefficients of variation were
obtained following software modification for which no explanation
is apparent. Patient sera, however, compared favorably both before
and after the software change ( A. = 0.997 and K. = 0.994).
Lactate Dehydrogenase
As shown in Table 16 the S-12 gave results very similar to the
12/60 for LDH. Virtually no bias was observed with patient serum
(1%) and only in one instance was a statistically significant bias
found in control material .
Aspartate Amino Transferase
The performance of the AST channel was judged to be unacceptable.
As shown in Table 17, the S-12 gave significantly higher coefficients
of variation for both controls before and after software modification.
The coefficient of variation for the normal control also exceed
the clinically acceptable value of 13.1% suggested by Cotlove (13).
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COMPARISON DATA
ALKALINE PHOSPHATASE
Within Run Precision
Day
' Mean CV. n
1 91.2 0.84 32
2 93.4 0.76 32
Day to Day Precision
Control 12/60 S-12 12/60 S-12
"" "F"
x (n) x (n) CV. CV. test test
Abnormal 126.4 (30) 128.0 (14) 2.36 2.71
Normal 36.2 (30) 33.8 (14) 6.26 3.96 +
Abnormal* 128.2 (30) 132.2 (8) 3.49 8.75 - +
Normal* 37.3 (30) 34.9 (8) 4.40 7.91 - +
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
'" test bias
+ -3.7
+ -5.4
n slope y-int K.
I 157 1.037 0.081 0.9972
II* 222 1.061 0.055 0.9937
*Data obtained after software modification.
TABLE 15
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COMPARISON DATA
LDH
Within Run Precision
ay Mean CV. n
1 296 1.38 32
2 302 1.72 32
Day to Day Precision
Control 12/60 S-12 12/60 S-12 "" "F"
x (n) x (n) CV. CV. test test
Abnormal 380.1 (30) 380.5 (14) 1.98 1.73
Normal 243.0 (30) 237.9 (14) 2.58 2.32 +
Abnormal* 371.7 (30) 376.6 (8) 2.73 3.15
Normal* 240.9 (30) 242.0 (8) 3.32 3.08 -
'
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
'"
test bias
1.5
+ 2.5
n slope y-int n.
I 124 1.022 -6.26 0.9863
II* 244 1.039 -10.33 0.9918
*Data obtained after software modification.
TABLE 16
38
COMPARISON DATA
AST
Within Run Precision
Day Mean CV. n
1 76.9 8.15 32
2 _ _ _ _
Day to Day Precision
Control 12/60 S-12 12/60 S-12 "" "F"
x (n) x (n) CV. CV- test test
Abnormal 111.2 (30) 127.4 (14) 4.72 7.14 + +
Normal 41.4 (30) 43.4 (14) 7.21 20.3 - +
Abnormal* 107.5 (30) 108.5 (8) 2.32 6.69 - +
Normal* 39.8 (30) 37.0 (8) 5.19 14.1 - +
Comparison of Patient Sera
SMA 12/60 (x) vs S-12 (y)
'"
test bias
+ -4.6
+ 1.5
n slope y-int A.
I 120 1.172 -2.81 0.9721
II* 186 1.121 -6.45 0.9898
*Data obtained after software modification.
TABLE 17
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During the first trial significantly higher results were
obtained with the S-12 for both the abnormal control and patient
specimens. This problem was eliminated for the control after the
software change, however, patient serum still showed a substantial
proportional difference (12%).
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Operational Parameters
The S-12 System does not allow for the attainment of a steady
state, hence there is an increased potential for the occurrence
of erroneous results due to minor chemical and hydraulic fluctuations.
Figure 1 illustrates the deformation of a typical 12/60 chemistry
curve which may result from one of several hydraulic problems.
Note, that while the slope of the rise curve is decreased, a steady
state is still obtained and the final result is unchanged. Figure 2
illustrates a similar situation that may occur with the S-12.
The S-12 microprocessor continuously monitors each curve, compares
the observed values with a standard (calibrator) curve and
2
calculates a value for the unknown. Any deformation in the chemistry
curve may, therefore, produce an erroneous value. To avoid the
reporting of misinformation a number of error detection algorithms
are incorporated into the microprocessor.
A record of S-12 error messages was kept during the course
of this study. Similar information was obtained for the 12/60.
Results are summarized in Table 18. Not all of the S-12 results
associated with error messages were erroneous. Indeed, in most
cases no substantial difference was observed between the S-12
results and the value obtained on the 12/60. This indicates that
the tolerance levels set for initiating an error message were too
stringent. Nevertheless, the observed error rates for total
protein, phosphorus, creatinine, bilirubin, alkaline phosphatase,
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Theoretical Deformation of a 12/60 Chemistry Curve
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Theoretical Deformation of an S-12 Chemistry Curve
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REJECTED VALUES
SMA 12/60 VS. S-12
TEST % REJECTED*
S-12
Total Protein 15.7
Albumin 1.2
Calcium 0.0
Phosphorus 11.8
Cholesterol 0.0
Urea 0.4
Uric Acid 0.0
Creatinine 5.2
Bilirubin 6.1
Alk Phos 8.1
LDH 2.0
AST 11.2
% REJECTED**
12/60
0. 3
0. 0
0. 0
0. 0
0,.0
0.,0
1.,1
1..8
0 .0
0 .0
0 .0
7 .4
* Based on receipt of error message
** Based on poor chemistry curve or control out of range
N = 250 for S-12 (8 days)
N = 337 for 12/60 (8 days)
TABLE 18
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LDH and AST were unacceptable for use in the routine clinical
laboratory.
Error rates are related to how well the 12/60 is maintained.
The maintenance program in use in this laboratory has proved
entirely adequate for the routine operation of the 12/60 over the
past two years. This program may not be entirely satisfactory for the
S-12 System and it is possible that a more extensive maintenance
program would result in fewer error messages.
Error rates also affect the degree of operator intervention.
Not only does the signaling of an error require immediate operator
intervention but the diagnosis of the problem may be lengthy
because the cause of the error may not be readily apparent. In
fact most S-12 error messages resulted from causes so subtle that
even the most experienced technologists had difficulty in locating
the source. Thus to operate the S-12 System effectively a highly
skilled, experienced technologist would be required. Furthermore,
the System could be left unattended for only short periods of time.
Conclusion
Table 19 summarizes the results of this study. Based on these
findings the S-12 System was deemed inadequate for routine use in
this laboratory.
Several modifications that might improve the System's performance,
were suggested to the manufacturer. Two major suggestions proposed
were:
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SUMMARY OF S-12 STUDY
Test
Error
Carryover Drift Linearity Precision Comparison Rate
Protein A A A A A NA
Albumin A A A A A A
Calcium NA NA A NA NA A
Phosphorus A A A A A NA
Cholesterol A A A A A A
Urea A A A A A A
Uric Acid A A A A A A
Creatinine A A A A A NA
Bilirubin A A A A A NA
Alk Phos A A A A A NA
LDH A A A A A A
AST NA NA A NA NA NA
NA - not acceptable
A - acceptable
TABLE 19
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1) decrease the sampling rate from 120 per hour to 90 per hour
2) decrease the sensitivity of error detection for certain channels.
No attempt was made by the manufacturer to incorporate these
suggestions into the System. The manufacturer discontinued further
sale of the S-12 System during September, 1977.
FOOTNOTES
1) Sherwood S-12 System manufactured by Sherwood Medical Industries,
Saint Louis, Missouri.
2) The exact formula used for this calculation was deemed proprietary
information by the manufacturer and was not available.
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ABBREVIATIONS
Alk Phos alkaline phosphatase (EC 3.1.1.1)
AST aspartate aminotransferase (EC 2.6.1.1)
CV coefficient of variation
DEC Data Equipment Corporation
dl deciliter
g gram
IPA abnormal control
IPN normal control
IU International Unit
1 liter
LDH lactate dehydrogenase (EC 1.1.1.27)
mg milligram
A correlation coefficient
S-12 Sherwood S-12 System
SD standard deviation
SMA 12/60
12/60 Sequential Multiple Analyzer
y-int y intercept
+ indicates significant difference at p<0.05
indicates no significant difference at p<0.05
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Linear Regression Graphs
The graphs derived by linear regression analysis of the data
obtained from analysis of patient serum prior to software modification
are found on pages 53 through 63. The results obtained following
software modification are found on pages 64 through 75. Each
point represents one patient serum specimen. In all cases the
SMA 12/60 results are plotted on the abscissa and 1>he S-12 results
are plotted on the ordinate.
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SUGGESTED CLINICALLY ACCEPTABLE
CO-EFFICIENTS OF VARIATION FOR DAY-TO-DAY PRECISION
Determination Barnett
Calcium 2.3
Phosphate 5.6
Bilirubin 20.0
Total Protein 4.3
Albumin 7.1
Uric Acid 8.3
Urea 7.4
Cholesterol
AST
LDH
Cotlove Average
1.6 1.95
6.6 6.1
3.2 3.75
3.5 5.3
12.3 10.3
7.5 7.4-5
8.2 8.2
13.1 13.1
9.1 9.1
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